practicaldermatology.com
A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.
The study, based in Taiwan and published in the Journal of the American Academy of Dermatology, was titled, “Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis.”
It aimed to investigate whether IL-17, IL-12/23, and IL-23 inhibitors were associated with differences in MACE/VTE risks compared with TNF inhibitors in biologic-naïve patients with psoriasis or psoriatic arthritis. A total of 32,098 patients were included, and no significant differences in the risks of MACE or VTE were observed. Among patients with preexisting hyperlipidemia and diabetes mellitus, the risks of MACE and VTE actually were lower among patients using the new biologics than those using TNF inhibitors.
“These findings can serve as a reference to health care providers and patients when making clinical decisions, thereby also providing evidence for future pharmacovigilance research,” the authors concluded.